Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in Relapse

Last updated: March 25, 2025
Sponsor: Rennes University Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Leukemia

Treatment

Sampling bone tissue and blood

Clinical Study ID

NCT06649253
35RC23_8885_REALLCD9
  • Ages < 17
  • All Genders

Study Summary

B-acute lymphoblastic leukaemia (B-ALL) is the most common cancer in children, with 20% of patients relapsing. CD9, a transmembrane protein, is linked to the migratory and adhesion capacities of leukaemia cells and could be associated with relapses. The aim of this project is to understand how CD9 regulation can be a marker of potential relapses, using bone and blood sampling of newly diagnosed patients at 3 crucial moments of therapy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Under 18 years

  • With established diagnosis of B-ALL

  • Initial diagnosis made in the investigating centre

  • Having received oral and written information about the protocol, or oral only if thepatient is unable to read.

  • Having signed a consent form if the patient is capable of giving informed writtenconsent.

  • Whose legal guardians have received oral and written information about the protocol,and have signed a free, informed and written consent.

  • Beneficiary of a social security scheme

Exclusion

Exclusion Criteria:

  • Isolated extramedullary involvement at inclusion

  • Patient of childbearing age without effective contraception.

  • Adult subject to legal protection (safeguard of justice, curatorship, guardianship),person deprived of liberty.

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: Sampling bone tissue and blood
Phase:
Study Start date:
March 22, 2025
Estimated Completion Date:
April 30, 2035

Study Description

B-acute lymphoblastic leukaemia (B-ALL) is the most common cancer in children, with 20% of patients relapsing despite major therapeutic advances. A research team of the Development and Genetic Institute in Rennes has identified that the expression of CD9, a transmembrane protein, is linked to the migratory and adhesion capacities of leukaemia cells, enabling them to persist in niches such as the testis. CD9-associated relapses often arise from these niches. Understanding the regulation of CD9 expression is therefore essential.

The hypothesis on which this project is based is that CD9 expression could be orchestrated by ncRNAs. Due to the complexity of deciphering circRNA-miRNA-mRNA networks, an exploration of patient blasts is envisaged in order to delineate a specific non-coding RNA network regulating CD9 expression from bone marrow and blood samples of paediatric-aged patients with B-ALL. If this hypothesis is confirmed, the ncRNAs identified could constitute new specific diagnostic and prognostic markers, or even therapeutic targets.

To confirm this hypothesis, bone and blood sampling of newly diagnosed patients will be collected at the diagnosis, after first phase of treatment and at the relapse, if it occurs.

Connect with a study center

  • CHU Angers

    Angers,
    France

    Active - Recruiting

  • CHU Brest

    Brest,
    France

    Active - Recruiting

  • CHU Rennes

    Rennes,
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.